Framing Eighteen Coils in Cerebral Aneurysms Trial (FEAT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01655784|
Recruitment Status : Recruiting
First Posted : August 2, 2012
Last Update Posted : November 17, 2017
This trial is being conducted in order to compare angiographic outcomes in patients receiving 0.014-0.0155" platinum framing and filling coils (larger diameter coils) versus those treated solely with coils less than 0.014" (with a standard diameter).
Hypothesis: Angiographic occlusion at follow-up imaging will be more frequent in patients receiving 0.014-0.0155" platinum coils during embolization compared to those receiving smaller-diameter coils.
|Condition or disease||Intervention/treatment|
|Cerebral Aneurysm||Procedure: Coil Embolization with larger Diameter Coils Procedure: Coil Embolization with Standard Diameter Coils|
Primary Study Objective: Occlusion rate: angiographic occlusion, improvement or no change in the post-coiling appearance of the aneurysm as judged by an independent core lab on follow-up angiography at 12-18 months after endovascular embolization.
- Treatment related morbidity and mortality, as measured by the NIH stroke scale.
- Packing density as measured by volumetric filling of the aneurysm.
- Clinical outcome at 3-6 and 12-18 months post-coiling, as measured by the modified Rankin scale.
- Re-hemorrhage and re-treatment rates.
Study Design: FEAT will be a prospective, randomized trial comparing the utilization of 0.014-0.0155" coils versus smaller diameter coils in mid-sized aneurysm treatment. The 0.014-0.0155" bare platinum coils (Stryker, Natick, MA) are FDA-approved and in common use at institutions in this country and across the world. Patients will be enrolled who meet the inclusion criteria and consent to participate. Patients will be randomly assigned by a central web-based system in a 1:1 manner to either the framing coil treatment or the non-framing coil treatment. Data on each patient will be collected at the time of enrollment and treatment, and at first and second follow-up visits.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||660 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Framing Eighteen Coils in Cerebral Aneurysms Trial: FEAT|
|Study Start Date :||August 2012|
|Estimated Primary Completion Date :||January 2019|
|Estimated Study Completion Date :||January 2019|
Active Comparator: Eighteen Coils (0.014-0.0155 inch)
Subjects who randomize to this arm will receive larger diameter bare platinum coils for treatment of their cerebral aneurysm. Subjects in this arm could receive a combination of the following protocol approved intracranial coils depending on the phase: Target XL 360 Standard, Target XL 360 Soft, Target XL 360 Helical, GDC-18 360 Standard, GDC-18 3D, GDC-18 2D, GDC-18 Soft, and/or 0.014-0.0155 inch diameter bare platinum intracranial coils.
Procedure: Coil Embolization with larger Diameter Coils
Eighteen Coils placed in cerebral aneurysm
Active Comparator: Standard Coils (0.014 inch)
Subjects who randomize to this arm will receive the standard diameter bare platinum coils for treatment of their cerebral aneurysm. Subjects in this arm could receive a combination of the following protocol approved intracranial coils depending on the phase: Target 360 Standard, Target 360 Soft, Target 360 Ultra, Target 360 NANO, Target 360 Helical Ultra, GDC-10 360 Standard SR, GDC-10 360 Soft SR, GDC-10 UltraSoft, GDC-10 3D, GDC-10 2D, GDC-10 Soft 2D SR, GDC-10 Soft SR, GDC-10 Soft, and/or any additional 0.014 inch or less diameter bare platinum intracranial coils.
Procedure: Coil Embolization with Standard Diameter Coils
Cerebral aneurysms will be embolized with standard diameter coils.
- Occlusion Rate [ Time Frame: 12-18 Month Follow-up ]Occlusion rate: Angiographic occlusion, improvement or no change in the post-coiling appearance of the aneurysm as judged by an independent core lab on follow-up angiography at 12-18 months after endovascular embolization.
- Morbidity [ Time Frame: Entire Study Duration (from signed research consent until 12-18 month follow-up complete) ]Morbidity will be measured by the NIH Stroke Scale and tracked regardless of whether it is related to the study procedure.
- Packing Density [ Time Frame: Post-Procedure (images taken during the procedure immediately after the coils are placed will be assessed) ]Packing density will be measured by volumetric filling of the aneurysm by reviewing post-op angiographic films.
- Clinical Outcome [ Time Frame: 3-6 Month Follow-up and 12-18 Month Follow-up ]Clinical outcome at both follow-up time points will be measured by the modified Rankin Scale.
- Re-hemorrhage and Re-treatment Rates [ Time Frame: 3-6 Month Follow-up and 12-18 Month Follow-up ]Re-hemorrhage rates will be tracked and recorded during both follow-up time points.
- Mortality [ Time Frame: Entire Study Duration (from study procedure until 12-18 month follow-up) ]Mortality will be tracked throughout the study and recorded regardless of whether it is related to treatment.
- Retreatment [ Time Frame: 3-6 Month Follow-up and 12-18 Month Follow-up ]Retreatment rates will be tracked and recorded during both follow-up time points.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01655784
|Contact: Stephanie A Smith, M.A.||6159360815||Stephanie.Anne.Smith@vanderbilt.edu|
Show 25 Study Locations
|Principal Investigator:||J D Mocco, MD, MS||Icahn School of Medicine at Mount Sinai|